Company profile
Molecule Holdings Inc.
OTC: EVRRF · Healthcare · Drug Manufacturers - Specialty & Generic
Canadian filerHQ Lansdowne, ONReports USD
#827 of 1,418 Healthcare companies by revenuetop-decile growth
EA Score
——FH —DQ —GM —SS 30
v0.1 · 5/100 weight · pillars only
↑ revenue growth (YoY), Piotroski F · ↓ balance-sheet leverage, disclosure history
Methodology →Revenue TTM
$1.3M
Rev growth YoY (TTM)
+6.4%
Net income (FY)
-$3.5M
Employees
13
as of 2026-08-26
Market cap
$626.1k
as of 2026-08-26
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$1.5M2.0M CAD2022
Net income-$3.5M-4.5M CAD2022
Operating income-$3.0M-3.9M CAD2022
Total assets$2.9M3.9M CAD2022
Liabilities$5.6M7.6M CAD2022
Equity-$2.7M-3.7M CAD2022
Revenue trend
FY2019 – FY2022 · USD
FY19
FY20
FY21
FY22
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Molecule Holdings Inc.’s revenue?
Molecule Holdings Inc. booked $1.5M in FY2022 revenue, growing 322% year over year — faster than 92% of Healthcare companies we track, at a -230.8% net margin.
Peers · Healthcare
Acura Pharmaceuticals, Inc.——Celldex Therapeutics, Inc.58COrthometrix, Inc.——New Leaf Ventures Inc——St. Joseph, Inc.67BStatera Biopharma, Inc.——Key facts
CEODavid Reingold
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersLansdowne, ON
ExchangeOTC: EVRRF
Employees13
IPO date2020-09-22
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.